vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Varex Imaging Corp (VREX). Click either name above to swap in a different company.
Varex Imaging Corp is the larger business by last-quarter revenue ($209.6M vs $191.2M, roughly 1.1× Axsome Therapeutics, Inc.). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (57.4% vs 4.9%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs 0.8%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Varex Imaging Corp is a global supplier of advanced imaging components and solutions, including X-ray tubes, digital flat panel detectors, and image processing software. Its products serve medical imaging, radiation oncology, and industrial non-destructive testing segments, with customers across key global markets.
AXSM vs VREX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $209.6M |
| Net Profit | — | $2.3M |
| Gross Margin | — | 33.3% |
| Operating Margin | -33.1% | 7.3% |
| Net Margin | — | 1.1% |
| Revenue YoY | 57.4% | 4.9% |
| Net Profit YoY | — | 866.7% |
| EPS (diluted) | — | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | $209.6M | ||
| Q4 25 | $196.0M | $228.9M | ||
| Q3 25 | $171.0M | $203.0M | ||
| Q2 25 | $150.0M | $212.9M | ||
| Q1 25 | $121.5M | $199.8M | ||
| Q4 24 | $118.8M | — | ||
| Q3 24 | $104.8M | $205.7M | ||
| Q2 24 | $87.2M | $209.1M |
| Q1 26 | — | $2.3M | ||
| Q4 25 | $-28.6M | $12.2M | ||
| Q3 25 | $-47.2M | $-89.1M | ||
| Q2 25 | $-48.0M | $6.9M | ||
| Q1 25 | $-59.4M | $-300.0K | ||
| Q4 24 | $-74.9M | — | ||
| Q3 24 | $-64.6M | $-51.1M | ||
| Q2 24 | $-79.3M | $1.4M |
| Q1 26 | — | 33.3% | ||
| Q4 25 | — | 34.0% | ||
| Q3 25 | — | 33.3% | ||
| Q2 25 | — | 36.0% | ||
| Q1 25 | — | 34.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 32.6% | ||
| Q2 24 | — | 32.0% |
| Q1 26 | -33.1% | 7.3% | ||
| Q4 25 | -13.8% | 8.6% | ||
| Q3 25 | -27.0% | -39.8% | ||
| Q2 25 | -24.5% | 10.4% | ||
| Q1 25 | -46.9% | 5.6% | ||
| Q4 24 | -61.1% | — | ||
| Q3 24 | -59.8% | 5.3% | ||
| Q2 24 | -89.5% | 4.4% |
| Q1 26 | — | 1.1% | ||
| Q4 25 | -14.6% | 5.3% | ||
| Q3 25 | -27.6% | -43.9% | ||
| Q2 25 | -32.0% | 3.2% | ||
| Q1 25 | -48.9% | -0.2% | ||
| Q4 24 | -63.1% | — | ||
| Q3 24 | -61.7% | -24.8% | ||
| Q2 24 | -91.0% | 0.7% |
| Q1 26 | — | $0.05 | ||
| Q4 25 | $-0.55 | $0.29 | ||
| Q3 25 | $-0.94 | $-2.15 | ||
| Q2 25 | $-0.97 | $0.17 | ||
| Q1 25 | $-1.22 | $-0.01 | ||
| Q4 24 | $-1.54 | — | ||
| Q3 24 | $-1.34 | $-1.25 | ||
| Q2 24 | $-1.67 | $0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | $125.6M |
| Total DebtLower is stronger | $70.0M | $367.6M |
| Stockholders' EquityBook value | — | $476.9M |
| Total Assets | $713.6M | $1.1B |
| Debt / EquityLower = less leverage | — | 0.77× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | $125.6M | ||
| Q4 25 | $322.9M | $155.1M | ||
| Q3 25 | $325.3M | $152.6M | ||
| Q2 25 | $303.0M | $223.0M | ||
| Q1 25 | $300.9M | $212.6M | ||
| Q4 24 | $315.4M | — | ||
| Q3 24 | $327.3M | $200.5M | ||
| Q2 24 | $315.7M | $190.0M |
| Q1 26 | $70.0M | $367.6M | ||
| Q4 25 | — | $367.5M | ||
| Q3 25 | — | $367.5M | ||
| Q2 25 | — | $567.2M | ||
| Q1 25 | — | $567.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $443.4M | ||
| Q2 24 | — | $443.1M |
| Q1 26 | — | $476.9M | ||
| Q4 25 | $88.3M | $472.6M | ||
| Q3 25 | $73.7M | $455.3M | ||
| Q2 25 | $73.1M | $549.7M | ||
| Q1 25 | $53.2M | $540.2M | ||
| Q4 24 | $57.0M | — | ||
| Q3 24 | $92.9M | $529.1M | ||
| Q2 24 | $102.9M | $581.2M |
| Q1 26 | $713.6M | $1.1B | ||
| Q4 25 | $689.8M | $1.1B | ||
| Q3 25 | $669.3M | $1.1B | ||
| Q2 25 | $639.8M | $1.4B | ||
| Q1 25 | $596.7M | $1.3B | ||
| Q4 24 | $568.5M | — | ||
| Q3 24 | $561.5M | $1.2B | ||
| Q2 24 | $548.2M | $1.3B |
| Q1 26 | — | 0.77× | ||
| Q4 25 | — | 0.78× | ||
| Q3 25 | — | 0.81× | ||
| Q2 25 | — | 1.03× | ||
| Q1 25 | — | 1.05× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.84× | ||
| Q2 24 | — | 0.76× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-16.1M |
| Free Cash FlowOCF − Capex | — | $-26.8M |
| FCF MarginFCF / Revenue | — | -12.8% |
| Capex IntensityCapex / Revenue | — | 5.1% |
| Cash ConversionOCF / Net Profit | — | -7.00× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-13.3M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $-16.1M | ||
| Q4 25 | $-18.7M | $7.9M | ||
| Q3 25 | $1.0M | $7.7M | ||
| Q2 25 | $-32.4M | $16.6M | ||
| Q1 25 | $-43.4M | $9.5M | ||
| Q4 24 | $-26.2M | — | ||
| Q3 24 | $-18.6M | $25.9M | ||
| Q2 24 | $-30.1M | $8.0M |
| Q1 26 | — | $-26.8M | ||
| Q4 25 | $-18.7M | $2.3M | ||
| Q3 25 | $988.0K | $1.4M | ||
| Q2 25 | $-32.4M | $9.8M | ||
| Q1 25 | $-43.7M | $5.3M | ||
| Q4 24 | $-26.2M | — | ||
| Q3 24 | $-18.7M | $19.9M | ||
| Q2 24 | $-30.2M | $3.3M |
| Q1 26 | — | -12.8% | ||
| Q4 25 | -9.6% | 1.0% | ||
| Q3 25 | 0.6% | 0.7% | ||
| Q2 25 | -21.6% | 4.6% | ||
| Q1 25 | -36.0% | 2.7% | ||
| Q4 24 | -22.1% | — | ||
| Q3 24 | -17.9% | 9.7% | ||
| Q2 24 | -34.6% | 1.6% |
| Q1 26 | — | 5.1% | ||
| Q4 25 | 0.0% | 2.4% | ||
| Q3 25 | 0.0% | 3.1% | ||
| Q2 25 | 0.0% | 3.2% | ||
| Q1 25 | 0.3% | 2.1% | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.1% | 2.9% | ||
| Q2 24 | 0.1% | 2.2% |
| Q1 26 | — | -7.00× | ||
| Q4 25 | — | 0.65× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 2.41× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 5.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
VREX
| Medical Segment | $144.8M | 69% |
| Industrial Segment | $64.8M | 31% |
